High FGR protein expression associated with worse relapse-free survival in de novo DLBCL patients treated with R-CHOP
New Protein Test Predicts Lymphoma Relapse Risk
This retrospective cohort study evaluated 91 patients with de novo diffuse large B-cell lymphoma treated with R-CHOP.
A new protein test identifies diffuse large B-cell lymphoma patients at high risk of relapse before treatment fails, giving doctors a crucia…
High-dose pegylated liposomal doxorubicin shows comparable survival to conventional doxorubicin in DLBCL with reduced toxicity
A Gentler Chemo Version Holds Its Own in Lymphoma
A retrospective cohort of 512 DLBCL patients found comparable 2-year PFS (74.3% vs.
A gentler chemo drug wrapped in fat bubbles matched standard treatment for lymphoma survival while sharply cutting serious side effects like…
Phase 2 trial compares Inotuzumab Ozogamicin plus R-CVP for DLBCL patients unfit for anthracycline
Can a new drug combination help lymphoma patients who can't take standard chemo?
A Phase 2 interventional trial enrolled 129 patients with diffuse large B-cell lymphoma (DLBCL) who were unsuitable for anthracycline-contai…
A new drug combo aims to treat aggressive lymphoma in older patients who can't take standard chemo due to heart risks.
CD5-positive DLBCL diagnosed in a 74-year-old woman via uterine drainage fluid analysis
Rare uterine lymphoma case highlights need for careful diagnosis in older women
This case report with literature review describes the diagnosis of CD5-positive diffuse large B-cell lymphoma (DLBCL) in a 74-year-old woman…
A rare uterine cancer in a 74-year-old woman mimics common conditions, so doctors must check for specific cell markers to avoid missing the …
Case report describes treatment response in rare dual-lesion DLBCL with heterogeneous subtypes
Doctors describe treatment response in rare case of dual-lesion lymphoma
A case report and systematic review describes a 65-year-old female with rare dual-lesion DLBCL featuring both GCB and ABC subtypes.
Doctors treated a woman with two different rare lymphoma types in her brain and muscle, achieving stability after adjusting her chemotherapy…
Research across Non-Hodgkin's Lymphoma
Related studies from across the Non-Hodgkin's Lymphoma family.
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
Adding stem cell transplant to ibrutinib treatment offered no extra benefit for lymphoma patients
In younger patients with mantle cell lymphoma, adding ASCT to an ibrutinib regimen did not improve outcomes but increased toxicity. Ibrutini…
Adding stem cell transplant to ibrutinib did not improve survival for younger lymphoma patients but increased side effects.
Systematic landscape analysis of CAR-T trials for non-Hodgkin lymphoma finds early-phase focus
CAR-T Trials Show Promise But Face Big Hurdles For Lymphoma Patients
This systematic landscape review of 360 CAR-T cell therapy trials for non-Hodgkin lymphoma found rapid expansion with a predominant focus on…
New research shows that CAR-T cell trials are expanding quickly but scientists must solve big problems like drug resistance before patients …
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications
FDA approves Revlimid for several blood cancers and related conditions.
FDA approved Revlimid (lenalidomide) for multiple myeloma (in combination with dexamethasone and as maintenance after auto-HSCT), transfusio…
The FDA approved Revlimid (lenalidomide) for multiple myeloma, certain myelodysplastic syndromes, mantle cell lymphoma, and other lymphomas.…
Fixed-duration subcutaneous mosunetuzumab shows favorable efficacy and safety versus IV in relapsed follicular lymphoma
Subcutaneous Mosunetuzumab Shows Promise for Follicular Lymphoma Patients
This Phase 2 primary analysis evaluated fixed-duration subcutaneous mosunetuzumab versus mosunetuzumab IV in patients with relapsed or refra…
A Phase 2 trial found subcutaneous mosunetuzumab had lower rates of severe side effects than the IV version for treating follicular lymphoma…
Abexinostat showed a 69.5% objective response rate in relapsed follicular lymphoma patients
New Drug Shrinks Stubborn Lymphoma Tumors After Other Treatments Fail
This single-arm, multi-center phase 2 study evaluated abexinostat in 90 patients with relapsed or refractory follicular lymphoma who had rec…
A new treatment is helping some patients with stubborn lymphoma shrink tumors and stay in control for over a year, even after other therapie…
Review of case report discusses anti-PL-12 antisynthetase syndrome and NK/T-cell non-Hodgkin lymphoma
Patient with anti-PL-12 syndrome and lymphoma: a rare case report
This review of a case report describes a patient with anti-PL-12 antisynthetase syndrome and NK/T-cell non-Hodgkin lymphoma.
A single patient with anti-PL-12 antisynthetase syndrome and NK/T-cell lymphoma highlights the need for caution when interpreting rare cance…
Narrative review explores strategies to prevent CAR-T cell exhaustion in treatment-resistant non-Hodgkin lymphoma
New Strategies to Keep CAR-T Cells Strong Against Cancer
This narrative review examines strategies to prevent CAR-T cell exhaustion in patients with treatment-resistant non-Hodgkin lymphoma.
This review explains how to stop immune cells from giving up on fighting cancer.
Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates
New treatments show high response rates for advanced follicular lymphoma patients
This systematic review and meta-analysis evaluated outcomes for patients with follicular lymphoma experiencing disease progression within 24…
New powerful medicines help 91% of advanced follicular lymphoma patients whose disease returned quickly after treatment.
Mitoxantrone liposome plus CMOP shows high response rates in untreated peripheral T-cell lymphoma patients
New Drug Combo Helps Most Patients With Hard-to-Treat Lymphoma
This phase 1b multicenter clinical trial evaluated mitoxantrone hydrochloride liposome combined with cyclophosphamide, vincristine, and pred…
A new drug combo wrapped in fat bubbles helped 89% of patients with hard-to-treat lymphoma shrink tumors without causing deaths.
Systematic review finds highest glyphosate exposure associated with increased NHL risk
Higher glyphosate herbicide exposure linked to increased lymphoma risk in research review
A systematic review and meta-analysis of 20 observational study populations found that ever exposure to glyphosate-based herbicides was not …
People with the highest glyphosate herbicide exposure had about a 38% higher chance of developing non-Hodgkin's lymphoma compared to those w…
R-CVP after radiotherapy improves progression-free survival in early-stage follicular lymphoma
Can adding a drug cocktail to radiation help keep early lymphoma from returning?
In a multicenter RCT with 150 patients with early-stage follicular lymphoma and 11.3-year median follow-up, involved-field radiotherapy plus…
Adding R-CVP drugs to radiation therapy helps early-stage lymphoma patients stay cancer-free longer, with mostly temporary side effects and …
Case report describes management of Burkitt's lymphoma with concurrent HIV, CMV encephalitis, and salmonella bacteremia
Case report describes complex treatment for man with lymphoma, HIV, and infections
A case report describes a 50-year-old man with newly diagnosed HIV, stage IV Burkitt's lymphoma with CNS and marrow involvement, CMV viremia…
Doctors managed a 50-year-old man with newly diagnosed HIV, aggressive lymphoma, and multiple serious infections through coordinated care fr…